Finance

Beta
Lists
8AK:FRA
Alkermes Plc
€36.95
+1.34%
(+0.49) 1D
Jun 5, 8:12:45 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 8AK...
Open
€36.95
High
€36.95
Low
€36.95
Mkt. cap
7.19B
Avg. vol.
5.00
Volume
0.00
52-wk high
€36.95
52-wk low
€22.00
No. of employees
2K
Open
€36.95
High
€36.95
Low
€36.95
Mkt. cap
7.19B
Avg. vol.
5.00
Volume
0.00
52-wk high
€36.95
52-wk low
€22.00
No. of employees
2K
News stories
From sources across the web
Profile
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. Wikipedia
About Alkermes Plc
CEORichard F. Pops | Richard F. Pops
Employees2.05K
Founded1987
Headquarters-
SectorBiotechnology
Websitealkermes.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
390.66M
394.18M
384.55M
392.91M
Cost of goods sold
49.46M
51.59M
46.21M
48.85M
Cost of revenue
49.46M
51.59M
46.21M
48.85M
Research and development expenses
74.07M
78.54M
89.74M
100.08M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
174.15M
174.97M
190.50M
233.06M
Operating expense
248.22M
253.51M
280.23M
344.81M
Total operating expenses
297.68M
305.10M
326.44M
393.66M
Operating income
92.98M
89.08M
58.10M
-754.00K
Other non operating income
771.00K
-280.00K
1.42M
-1.29M
EBT including unusual items
104.84M
100.74M
60.38M
-61.93M
EBT excluding unusual items
104.84M
100.74M
60.38M
-14.40M
Income tax expense
17.74M
17.98M
11.04M
4.55M
Effective tax rate
16.92%
17.85%
18.28%
-7.35%
Other operating expenses
-
-
-
-
Net income
87.10M
82.76M
49.34M
-66.48M
Net profit margin
22.30%
21.00%
12.83%
-16.92%
Earnings per share
0.68
0.65
0.48
0.38
Interest and investment income
11.09M
11.94M
12.13M
8.54M
Interest expense
-
-
-12.28M
-20.89M
Net interest expenses
11.09M
11.94M
-147.00K
-12.35M
Depreciation and amortization charges
-
-
-
-
EBITDA
100.80M
97.16M
61.95M
18.68M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer